Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Launched by ASTRAZENECA · Oct 16, 2009
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cancer)
Gender
ALL
Eligibility criteria
- • Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV). Mixed histology of small cell and non-small cell lung cancer
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Erlangen, , Germany
Essen, , Germany
Hamburg, , Germany
Mainz, , Germany
Freiburg, , Germany
Heidelberg, , Germany
Leipzig, , Germany
Minden, , Germany
Wiesbaden, , Germany
Augsburg, , Germany
Regensburg, , Germany
Frankfurt, , Germany
Ulm, , Germany
Bonn, , Germany
Leverkusen, , Germany
Mannheim, , Germany
Stuttgart, , Germany
Koblenz, , Germany
Tubingen, , Germany
Aachen, , Germany
Hannover, , Germany
Magdeburg, , Germany
Munchen, , Germany
Rostock, , Germany
Homburg, , Germany
Saarbrucken, , Germany
Recklinghausen, , Germany
Oldenburg, , Germany
Aschaffenburg, , Germany
Dresden, , Germany
Kiel, , Germany
Jena, , Germany
Stralsund, , Germany
Dortmund, , Germany
Halle, , Germany
Dusseldorf, , Germany
Marburg, , Germany
Bochum, , Germany
Grobhansdorf, , Germany
Kassel, , Germany
Koln, , Germany
Celle, , Germany
Ludwigshafen, , Germany
Braunschweig, , Germany
Cottbus, , Germany
Esslingen, , Germany
Trier, , Germany
Gottingen, , Germany
Chemnitz, , Germany
Nurnberg, , Germany
Ansbach, , Germany
Paderborn, , Germany
Passau, , Germany
Sonneberg, , Germany
Hemer, , Germany
Karlsruhe, , Germany
Amberg, , Germany
Bayreuth, , Germany
Coswig, , Germany
Darmstadt, , Germany
Deggendorf, , Germany
Eisenach, , Germany
Flensburg, , Germany
Freising, , Germany
Fulda, , Germany
Hamm, , Germany
Moers, , Germany
Neuss, , Germany
Nordhausen, , Germany
Oberhausen, , Germany
Solingen, , Germany
Bad Berka, , Germany
Munster, , Germany
Rosenheim, , Germany
Wurzburg, , Germany
Bielefeld, , Germany
Lubeck, , Germany
Goslar, , Germany
Donaustauf, , Germany
Gieben, , Germany
Osnabruck, , Germany
Offenbach, , Germany
Volklingen, , Germany
Bamberg, , Germany
Mulheim, , Germany
Suhl, , Germany
Halle Dolau, , Germany
Luneburg, , Germany
Villingen Schwenningen, , Germany
Weiden, , Germany
Borstel, , Germany
Ostfildern, , Germany
Bottrop, , Germany
Dessau Rosslau, , Germany
Gerlingen, , Germany
Hof, , Germany
Landshut, , Germany
Lunen, , Germany
Offenburg, , Germany
Schonebeck, , Germany
Wurselen, , Germany
Ballenstedt, , Germany
Bitterfeld Wolfen, , Germany
Bremen, , Germany
Bremerhaven, , Germany
Greifenstein, , Germany
Immenhausen, , Germany
Lemgo, , Germany
Lostau, , Germany
Lowenstein, , Germany
Munnerstadt, , Germany
Northeim, , Germany
Querfurt, , Germany
Treuenbrietzen, , Germany
Velbert, , Germany
Wangen/Allgau, , Germany
Zusmarshausen, , Germany
Patients applied
Trial Officials
Prof. Dr. H. Brasch
Study Director
AstraZeneca Germany
PD Dr. med. Wolfgang Schutte
Principal Investigator
06120 Halle-Dolau, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials